CAPLIPOINT2024-01-012024-03-31 CAPLIPOINT2024-01-012024-03-31 CAPLIPOINT2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member CAPLIPOINT2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member CAPLIPOINT2024-03-31 CAPLIPOINT2024-01-012024-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member CAPLIPOINT2024-01-012024-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member CAPLIPOINT2024-01-012024-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member CAPLIPOINT2024-01-012024-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524742 CAPLIPOINT NOTLISTED Caplin Point Laboratories Limited Equity 2023-04-01 2024-03-31 2024-05-16 2024-05-09 INR Crores Yearly 11:45:00 13:30:00 2024-05-16 2024-05-16 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceutical Formualtions 2024-01-01 2024-03-31 Audited Consolidated 4532200000.00 172900000.00 4705100000.00 578700000.00 1217800000.00 117200000.00 367700000.00 1500000.00 164000000.00 798500000.00 3245400000.00 1459700000.00 600000.00 1460300000.00 205700000.00 42300000.00 248000000.00 0.00 1212300000.00 0.00 0.00 0.00 0.00 1212300000.00 32600000.00 1244900000.00 1215900000.00 -3600000.00 1248400000.00 -3600000.00 151900000.00 2 16.01 15.90 0.00 0.00 16.01 15.90 0.00 0.00 0.00 1. The above Consolidated Financial Results for the quarter and year ended March 31, 2024 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on May 16, 2024. 2. The Audited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder ( Ind AS ) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI ( Listing Obligations and Disclosure Requirments) Regulations, 2015. 3.The Company is engaged in the sole activity of carrying on the business of Pharmaceutical Formulation and therefore, has only one reportable segment in accordance with Ind AS 108 Operating Segments . Hence no separate segment reporting is applicable to the Company. 4. During the quarter ended and year ended March 31, 2024 the Company has alloted Nil and 39,000 equity shares of Rs. 2/- each under the Employees Stock Option Schemes respectively and the total number of equity shares of the Company stands at 7,59,41,746 as at March 31, 2024. The Company had allotted 10,500 shares and 1,13,870 shares during the quarter and year ended March 31, 2023 respectively and the total number of equity shares of the company stands at 7,59,02,746 as at March 31, 2023. 5. The Consolidated Results for the year ended March 31, 2024 presented above have been audited by the Statutory Auditors of the company. An unqualified opinion has been issued by them thereon. 6. The Board of Directors at their meeting held on May 16, 2024 approved an interim dividend of Rs…./- (….%) per equity share of Rs. 2/- each for the Financial Year 2023-24. 7. The figures for the quarter ended March 31, 2024 and March 31, 2023 are balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the relevant financial year, which have been subjected to limited review by the Statutory Auditors. 8. Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary. Single segment 2023-04-01 2024-03-31 Audited Consolidated 16941000000.00 669400000.00 17610400000.00 2398100000.00 5589200000.00 -745500000.00 1435900000.00 7800000.00 534400000.00 2748900000.00 11968800000.00 5641600000.00 2700000.00 5644300000.00 1015500000.00 14600000.00 1030100000.00 0.00 4614200000.00 0.00 0.00 0.00 0.00 4614200000.00 114500000.00 4728700000.00 4570800000.00 43300000.00 4685400000.00 43300000.00 151900000.00 2 0.00 60.19 59.90 0.00 0.00 60.19 59.90 0.00 0.00 0.00 Other Expenses 798500000.00 Other Expenses 2748900000.00 311200000.00 4386200000.00 1166200000.00 0.00 0.00 125200000.00 0.00 0.00 0.00 1376300000.00 0.00 0.00 126100000.00 1502400000.00 122000000.00 749600000.00 8051600000.00 3630400000.00 2379800000.00 5427200000.00 1387000000.00 4140400000.00 0.00 455400000.00 13789800000.00 0.00 1501900000.00 18922100000.00 0.00 0.00 26973700000.00 151900000.00 23005100000.00 23157000000.00 23468200000.00 9200000.00 0.00 104700000.00 113900000.00 86100000.00 0.00 0.00 0.00 200000000.00 2800000.00 2094200000.00 749000000.00 2846000000.00 356100000.00 103400000.00 0.00 0.00 3305500000.00 0.00 0.00 3505500000.00 26973700000.00 7800000.00 -748200000.00 -1486600000.00 0.00 -26000000.00 0.00 0.00 -14100000.00 0.00 693400000.00 0.00 0.00 0.00 534400000.00 0.00 0.00 0.00 0.00 0.00 -8600000.00 0.00 472800000.00 8500000.00 -8700000.00 0.00 0.00 0.00 114800000.00 0.00 -1406100000.00 4238200000.00 0.00 0.00 0.00 1091800000.00 -36600000.00 3109800000.00 0.00 0.00 0.00 937700000.00 0.00 0.00 0.00 0.00 0.00 1458100000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 437300000.00 0.00 -1167800000.00 0.00 -3126300000.00 0.00 0.00 0.00 0.00 0.00 0.00 100000.00 0.00 -31300000.00 0.00 0.00 0.00 341700000.00 7800000.00 0.00 0.00 -380700000.00 -397200000.00 8600000.00 -388600000.00 1775600000.00 1387000000.00 Remeasurements of Defined Benefit Plan -5400000.00 Remeasurements of Defined Benefit Plan -400000.00 -5400000.00 -400000.00 -1400000.00 -100000.00 Exchange difference in translating the financial statements of foreign operations 36600000.00 Exchange difference in translating the financial statements of foreign operations 114800000.00 36600000.00 114800000.00 0.00 0.00